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Abstract
Background: The prognosis of pancreatic ductal adenocarcinoma (PDAC) is worse when the tumor is located in
the pancreatic body or tail, compared to being located in the pancreatic head. However, for localized, resectable
tumors survival seems to be at least similar.
Methods: We analyzed and compared the outcome after pancreatoduodenectomy (PD) and distal pancreatectomy
(DP) for PDAC at our institution. Clinical, pathological and survival data from patients undergoing pancreatic
resection for PDAC 1994–2014 were explored retrospectively, accessing a prospective pancreatic database. Patients
receiving primary total pancreatectomy were excluded.
Results: Four hundred and thirteen patients were treated for PDAC: 347 (84 %) underwent PD and 66 (16 %) DP.
Tumors located in the pancreatic body and tail were significantly larger than their counterparts located in the head
(30.6 mm vs. 41.2 mm; p < 0.001). However, distal tumors had significantly less nodal involvement (71 % vs. 57 %;
p = 0.03). Portal-vein resection (PVR) was performed more often in PD, multivisceral resection (MVR) was more
frequent in DP (37 % vs. 14 % and 4 % vs. 29 %; p < 0.001). Rates for negative resection margins and tumor grading
were similar. Postoperative complication rates including morbidity, rates of re-operation and mortality were
comparable. Long-term outcome revealed no significant difference between PD and DP with 5-year survival rates of
17.8 and 22 % respectively (p = 0.284). Multivariate analysis confirmed positive resection margin, positive nodal
status, extended resection (PVR, MVR) and lack of adjuvant/additive chemotherapy as independent risk factors for
poor survival after pancreatic resection.
Conclusion: Patients with resectable pancreatic ductal adenocarcinoma located in the body and tail of the
pancreas display a similar postoperative oncological outcome despite larger tumors when compared to patients
with resectable tumors located in the pancreatic head.
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Background
Prognosis for pancreatic cancer (PC) has only slightly
improved over the past decades and still is grim, with a
current 5-year relative survival rate of about 6.9 % [1, 2].
Stratified by tumor site, mortality is even worse when
the tumor is located in the pancreatic body and tail. A
recent analysis based on SEER-data (Surveillance, Epi-
demiology and End Results Program by the National
Cancer Institute, NCI, U.S.) revealed a significant differ-
ence in the 3-year survival rates of 3.9 % (body/tail) vs.
6.2 % (head) [3]. This observation is most likely due to
delayed diagnosis in the case of tumor location in the
pancreatic body and tail, since early symptoms are usu-
ally lacking. Therefore, a significantly higher percentage
of patients is primarily diagnosed with advanced disease
and stage IV PC (body/tail: 56–73 % vs. head: 26–39 %)
[3, 4], where surgical therapy is not beneficial. Complete
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resection at an early stage though, is the most important
factor in multimodal treatment and the only chance for
cure and long-term survival [5]. In combination with
adjuvant chemotherapy, 5-year survival rates of up to
15–30 % can be achieved [6–9].
In the case of localized and resectable disease, some
observational studies analyzing the outcome by tumor
stage at diagnosis show superior survival for patients with
cancer located in the pancreatic body/tail compared to
patients with cancer located in the pancreatic head [3, 4].
A NCD-report (National Cancer Database, American
College of Surgeons Commission on Cancer and Ameri-
can Cancer Society) pictures a 5-year survival-rate of 32 %
(tail) vs. 11 % (head) for stage I disease (for stage II and
stage III disease 12 % (tail) vs. 6 % (head) and 11 % (tail)
vs. 7 % (head), respectively) [4]. However, when recently a
surgical collective of patients after pancreatic resection for
adenocarcinoma was examined, the survival benefit for
patients with resectable disease located in the body and
tail detected in these observational studies could yet not
be confirmed [10]. In this and other studies, despite sig-
nificantly larger size of tumors located in the body/tail,
survival after proximal pancreatectomy and distal pan-
createctomy was similar [6, 10–13].
To clarify these putative contradictions, our aim was
to retrospectively examine our own single-institution collect-
ive regarding survival after resection for pancreatic ductal
adenocarcinoma (PDAC). We intended to identify risk factors
influencing survival in patients undergoing distal pancreatec-
tomy (DP) or pancreatoduodenectomy (PD) for PDAC.
Methods
Patients
From July 1994 to December 2014, 413 patients with
primary non-metastasized pancreatic adenocarcinoma
were eligible for surgery (PD or DP) in our department
(patients requiring total pancreatectomy were not in-
cluded). 347 were treated by pancreatoduodenectomy
and 66 by distal pancreatectomy.
Surgical technique and pathological analysis
Whenever possible, the pylorus was preserved during
pancreatoduodenectomy. Complete lymphadenectomy
was performed in the hepatic ligament, right of the ce-
liac trunk and right of the mesenteric artery. Venous
structures were resected whenever necessary to achieve
complete resection. Intraoperative histopathologic evalu-
ation was routinely performed at common bile duct and
pancreatic resection margin. In recent years the mesopan-
creatic retroperitoneal margin was also examined. Other
margins underwent frozen section analysis if intraopera-
tively indicated, such as in case of venous resection at
both venous resection margins. In distal pancreatectomy
with splenectomy, lymphadenectomy was performed left
of the celiac trunk and left of the mesenteric artery. Since
2005 resection was performed as described by Strasberg et
al. [8, 14, 15] including the fascia of Gerota and when indi-
cated the left adrenal gland. Intraoperative histopathologic
evaluation was performed at the pancreatic resection mar-
gin. After formalin fixation, standard histopathological
evaluation was performed on all operative specimens in
which tumor size, lymph node status and resection margin
were assessed. Negative resection margin was defined as
tumor remote to the resection margin independent of the
exact distance.
Since 2006 laparoscopic procedures for DP as well as
PD increased in number. Pancreatic stump management
(DP) and reconstruction (PD) were accomplished via
mini-laparotomy.
Perioperative therapy
Neoadjuvant therapy was administered, in a few cases
(n = 22) with locally advanced disease since year 2000,
predominantly as radiochemotherapy. Postoperative ad-
juvant treatment was heterogeneous. In the early study
phase adjuvant therapy was not routinely performed after
curative resection. Since 2003 a few selected patients were
included in studies. Later, due to evidence from random-
ized trials (European Study Group for Pancreatic Cancer:
ESPAC-1 Trial) [16], adjuvant chemotherapy was regularly
recommended and administered. In case of positive resec-
tion margins postoperative chemoradiation or additive
chemotherapy was administered whenever applicable, pref-
erentially in clinical trials.
Follow-up and statistical analysis
Perioperative data was collected prospectively in a SPSS
database (IBM Corp. Released 2013. IBM SPSS Statistics
for Windows, Version 22.0. Armonk, NY: IBM Corp.)
The survival status was achieved from general practi-
tioners or oncologists (until 2001) and regional cancer
registries (since 2001). Data collection and analysis were
performed in accordance with the Helsinki guidelines
and approved by the local ethics committee (Ethik-Kom-
mission of the Albert-Ludwigs-Universtität Freiburg), the
need for individual verbal or written informed consent
from participants or their next of kin was waived. Statis-
tical analysis was performed with SPSS. In addition to
descriptive statistics, inferential analysis (χ2-test for cat-
egorical variables or Mann–Whitney-U-test for continu-
ous variables) and Kaplan-Meier survival analyses with
log-rank-test for the comparison of subgroups, multi-
variate analysis (Cox proportional hazards model) was
performed to determine independent risk factors.
Results
Of the 413 resected patients nine (2.2 %) died due to
postoperative complications, seven were lost to follow-
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up. Therefore, 16 patients were excluded for survival ana-
lysis (11 patients from the PD-group and 5 patients from
the DP-group). Survival was analyzed in the remaining
397 patients. Of those, 336 patients received PD while 61
patients were treated with DP. Median postoperative
follow-up was 14 months (13 months for deceased pa-
tients; 16 months for censored patients).
Patient characteristics
In both groups patient characteristics were not signifi-
cantly different in regard to gender, age and body mass
index (Table 1).
Surgery
Regarding duration of surgery, a significant difference
was detectable with PDs showing to be more time-
consuming (PD: 440 (245–760) min vs. DP: 301 (140–
717) min [median (range)]). If blood transfusions were
necessary, the volume administered was significantly
higher in the PD-group (PD: 423 ± 729 ml vs. DP: 192 ±
368 ml [mean ± SD]). The intraoperative involvement of
the superior mesenteric vein or portal vein with a subse-
quent resection was higher in patients with tumors lo-
cated in the pancreatic head (PD: 37 % vs. DP: 14 %). In
contrast, multivisceral resections were performed more
frequently in patients with tumors located in the
Table 1 Demographic, surgical, pathological and postoperative data from 413 patients undergoing pancreatic resection for
pancreatic ductal adenocarcinoma (1994–2014)
Pancreaticoduodenectomy Distal pancreatectomy p
N of resections 347 66
Gender 0.755
Male 182 [52 %] 36 [55 %]
Female 165 [48 %] 30 [45 %]
Age in years median (range) 67.0 (31–89) 65.6 (35–88) 0.362
BMI in kg/m2 median (range) 24.4 (7.6–38.8) 23.6 (18.2–35.4) 0.725
Operation time in min median (range) 440 (245–760) 301 (140–717) <0.001
PRBC receivedif received, vol. in ml mean (±SD) 135 [39 %] 17 [27 %] 0.056
423 (±729) 192 (±368) 0.024
Extended resection
- none 204 [59 %] 38 [58 %] <0.001
- portal vein 128 [37 %] 9 [14 %]
- multivisceral 15 [4 %] 19 [29 %]
Free resection margin 247 [71 %] 46 [73 %] 0.767
Gradinga
G1 11 [3 %] 5 [9 %] 0.229
G2 194 [57 %] 28 [51 %]
G3 128 [38 %] 21 [38 %]
G4 6 [2 %] 1 [2 %]
Tumor size in mm median (range) 28 (1–130) 38 (5–110) <0.001
Node positive 246 [71 %] 35 [57 %] 0.030
N of analyzed nodes median (range) 15 (2–47) 15 (2–32) 0.783
Any complication 181 [52 %] 32 [49 %] 0.584
Surgical complication 123 [35 %] 20 [30 %] 0.421
- POPF 48 [14 %] 25 [38 %] <0.001
- IAA 25 [7 %] 8 [12 %] 0.177
- SSI 44 [13 %] 6 [9 %] 0.413
Re-operation 33 [10 %] 10 [15 %] 0.169
Mortality 7 [2 %] 2 [3 %] 0.605
Adjuvant/additive chemotherapy 188 [54 %] 35 [53 %] 0.864
BMI body mass index, PRBC packed red blood cells, POPF postoperative pancreatic fistula, IAA intraabdominal abscess, SSI surgical site infection
aData for Tumor grading was not available for 19 patients (PD: 8 patients; DP: 11 patients)
Ruess et al. BMC Surgery  (2015) 15:123 Page 3 of 8
pancreatic body and tail (PD: 4 % vs. DP: 29 %). Here atyp-
ical gastric resections and colon resections were mostly
performed (data not shown). Resection of the left adrenal
gland was considered as frequent part of the procedure
for DP, therefore adrenalectomy was neglected when ana-
lyzing for multivisceral resections (Table 1).
Pathologic diagnosis
Tumors located in the pancreatic body and tail were sig-
nificantly larger than tumors located in the pancreatic
head (PD: 28 (1–130) mm vs. DP: 38 (5–110) mm [me-
dian (range)]. Despite larger tumors, margin negative
(R0) resection was achieved with an equal rate (PD:
71 % vs. DP: 73 %). Histopathologic evaluation showed a
comparable distribution of tumor grading. However,
nodal involvement was less frequent when the tumor
was located in the pancreatic body/tail (rate of N+: PD:
71 % vs. DP: 57 %, with similar median number of ana-
lyzed nodes) (Table 1).
Postoperative course
Postoperative complications of any kind and surgery re-
lated complications like pancreatic fistula, intraabdom-
inal abscess, or wound infection were not significantly
different between the two groups. However, evaluation
by specific surgical complication revealed significance
for a higher pancreatic fistula rate after distal resection.
Necessity of re-operation and mortality (PD: 2 % vs. DP:
3 %) was similar (Table 1).
Adjuvant/additive therapy
Two-hundred and twenty-three patients received or
were referred to oncologists to receive postoperative
chemotherapy. Twenty-two of these had additionally
been treated with neoadjuvant therapy for locally ad-
vanced, initially unresectable tumors; 62 had positive re-
section margins. The remaining group of 175 comprised
patients who were either not treated in an adjuvant/
additive manner (historical cohort or due to morbidity)
or for whom this data was lacking. The rate of adju-
vantly/additively treated patients did not differ between
the PD- (54 %) and DP-group (53 %) (Table 1).
Survival
The entire group of 397 patients showed an overall 3-
and 5-year survival after pancreatic resection of 29.5 and
18.3 % respectively with a median survival of 20.6 months
(95 % CI: 17.4–23.8).
A trend to increased survival (p = 0.284) was observed
in patients after surgery for tumors located in the pan-
creatic body and tail compared to those located in the
pancreatic head. The 3- and 5-year survival rates of
patients after pancreatoduodenectomy were 27.3 and
17.8 % compared to 45.5 and 22 % in patients treated
with distal pancreatectomy. The median survival in
patients after PD and DP was 20.4 months (95 % CI:
17.4–23.8) and 24.4 months (95 % CI: 2.9–45.8), respect-
ively (Table 2 and Fig. 1).
In the subgroups with negative resection margin 3-
year and 5-year survival rates were 33.7 and 21.1 % (PD)
vs. 54.2 and 25.3 % (DP), respectively (p = 0.212). In the
case of margin-positive resection, survival was consider-
ably worse with 3-year and 5-year survival rates of 13 and
11.2 % after PD vs. 17.5 % vs. 0 % after DP (p = 0.370)
(Fig. 2).
The Strasberg-approach for distal resection was per-
formed since 2005 on 20 out of 61 patients with follow-up
data. We could not detect a difference in survival between
the historical and the Strasberg-cohort (data not shown).
Adjuvant/additive chemotherapy significantly improved
oncological outcome after pancreatic surgery for PDAC.
The group of patients who received or intended to receive
adjuvant/additive therapy demonstrated a median survival
of 25.8 months (95 % CI: 20.6–31.0). However, patients
who did not receive adjuvant/additive therapy or for
whom this information was lacking had a median survival
of only 18 months (95 % CI: 14.9–21.1). 3-year and 5-year
survival rates were 37.3 and 14.9 % (received/intended to
receive) vs. 22 % and 15.7 % (not received/unknown),
respectively (p = 0.010) (Table 2 and Fig. 3).
Risk factors for survival
In univariate analysis resection margin, nodal disease,
extent of resection (portal vein and/or multivisceral),
blood transfusion and adjuvant/additive chemotherapy
showed significant impact on survival after pancreatic
resection for PDAC. No effect was observed for patient
gender, age and BMI. Furthermore, tumor size, tumor
grading and the presence of postoperative complications
also did not significantly affect survival (Table 2).
Multivariate survival analysis revealed resection mar-
gin, nodal disease, extended resection, and adjuvant/
additive chemotherapy as independent risk factors for
survival after pancreatic resection for PDAC (Table 3).
Discussion
Although stage-independent overall survival is worse for
distally located pancreatic cancer, better long-term out-
come for localized tumors of the pancreatic body/tail
has been reported. This is probably due to surgical ap-
proaches. Delayed diagnosis of pancreatic cancer, when
the tumor is located in the pancreatic body or tail, leads
to a higher number of patients not being amenable to
resection. Especially the lack of specific symptoms such
as jaundice is responsible for that fact. Most likely, de-
creased survival is rather due to systemic spread and
metastasis than to local unresectability. When located in
the pancreatic body and tail, compared to the pancreatic
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Table 2 Overall survival after resection for pancreatic ductal adenocarcinoma. Univariate survival analysis of 397 patients
Parameter n 3-year-survival 5-year-survival p
All 397 29.5 % 18.3 %
Tumor location
Head 336 27.3 % 17.8 %
Distal 61 45.4 % 22.0 % 0.284
Gender
Male 190 29.3 % 15.8 %
Female 207 29.7 % 20.2 % 0.683
Age
> 65 years 225 30.4 % 22.6 %
< 65 years 172 28.3 % 13.8 % 0.493
BMIa
> 25 kg/m2 161 26.3 % 13.7 %
< 25 kg/m2 235 31.2 % 20.9 % 0.494
Tumor sizea
< 30 mm 223 28.8 % 18.4 %
> 30 mm 157 30.4 % 16.9 % 0.860
Tumor gradinga
Grade 1 + 2 230 29.6 % 18.7 %
Grade 3 + 4 151 26.5 % 15.3 % 0.191
Resection margina
R0 283 36.2 % 21.7 %
R+ 113 13.5 % 9.9 % <0.001
Nodal statusa
Negative 121 41.1 % 27.7 %
Positive 272 22.9 % 13.0 % 0.001
Extended resection
None 233 35.9 % 26.1 %
Portal Vein (PV) 133 21.5 % 7.9 %
More than PV, multivisceral 31 12.8 % 0 % <0.001
PRBC transfusiona
Yes 143 22.4 % 15.6 %
No 252 33.8 % 19.2 % 0.005
Any complication
Yes 200 31.1 % 17.2 %
No 197 27.8 % 18.7 % 0.916
Surgical complication
Yes 133 37.0 % 18.1 %
No 264 25.9 % 17.4 % 0.149
Adjuvant/additive chemotherapy
Yes/Intendedb 222 37.3 % 14.9 %
No/Unknown 175 22.0 % 15.7 % 0.010
BMI body mass index, PRBC packed red blood cells
aSome parameters were not available for individual patients (BMI: 1 patient; Tumor size: 17 patients; Tumor grading: 16 patients; Resection margin: 1 patient;
Nodal status: 4 patients; PRBC transfusion: 2 patients)
bIncluded are 22 patients with (additional) neoadjuvant therapy and 62 patients with additive therapy
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head, larger tumors can be resected more frequently and
successfully, as measured by the rate of margin-free re-
sections. In spite of larger tumor size, similar long-term
outcome for DP and PD has been noted [6, 10–13].
One reason for this might be a favorable tumor biol-
ogy of resectable PDAC of the pancreatic body/tail.
Although the tumor grade usually increases with tumor
size [6], this could not be demonstrated in our analysis.
However, others have reported similar data with proximal
tumors showing more dedifferentiation in spite of smaller
size [17]. Similar to our study, nodal involvement seems
to be less frequent in resectable distal tumors [6, 17]. Con-
firmed here as independent risk factor, nodal disease is
well known to negatively correlate with survival [18–23].
Furthermore, technical advances in form of the radical
antegrade modular pancreatosplenectomy, described by
Strasberg et al. [14], may achieve higher rates of margin-
free resection. This has probably contributed to improved
survival-rates after DP in recent years [24]. Five-year-
survival-rates of up to 30 % are reported [8, 21]. However,
in our cohort we could not detect a survival benefit
related to this procedure.
Fig. 1 Kaplan-Meier plot: Survival analysis of 397 patients after
pancreatic resection for pancreatic ductal adenocarcinoma. Patients
after pancreatoduodenectomy (n = 336) vs. patients after distal
pancreatectomy (n = 61). 3-year and 5-year survival rates are 27,3
and 17.8 % (PD) vs. 45.4 and 22 % (DP). p = 0.284
Fig. 2 Kaplan-Meier plot: Survival analysis stratified by resection margins. a Patients with negative resection margin (R0), after pancreatoduodenectomy
(PD, n = 239) vs. distal pancreatectomy (DP, n = 44). b Patients with positive resection margin (R+), after PD (n = 97) vs. DP (n = 16)
Fig. 3 Kaplan-Meier plot: Survival analysis of 397 patients after
pancreatic resection for pancreatic ductal adenocarcinoma. Patients
who received or intended to receive adjuvant/additive chemotherapy
(n = 222) vs. patients who did not receive adjuvant/additive therapy or
with unknown status (n = 175)
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Another factor is the possibility of resecting adjacent
organs when involved in the tumor. Patients with tu-
mors located in the pancreatic body and tail benefit from
the fact that technically, distal pancreatectomies can be
easily performed together with en bloc gastric or colon
resections. Without the involvement of vital structures
as in the case of the pancreatic head with its anatomical
proximity to important vessels, this extended, or multi-
visceral resection is not only feasible but also safe and
justified [25–27]. Our pooled data for PD and DP dem-
onstrate that survival after portal vein (PVR) and espe-
cially multivisceral (MVR) resection is worse in contrast
to the standard procedure. However, this observation
may be biased by the skewed dataset in favor of PDs
where MVR or extended resection for pancreatic head
cancer is associated with increased perioperative risk
and with worse oncological outcome [28]. In our
study significantly more patients were able to undergo
multivisceral resections when presenting with tumors
of the pancreatic body/tail. Morbidity and mortality
were not different between the two groups. Rates of
margin-free resection were similar. As our data
undermine (Table 2+3, Fig. 2), R0-resection is the
mainstay of surgical therapy and one of the most im-
portant factors influencing long-term outcome [6, 17,
19, 29, 30]. However, it is to be completed by adju-
vant chemotherapy (Table 2+3, Fig. 3) whenever pos-
sible [9].
Although this study is limited by its retrospective char-
acter, in summary our collective demonstrates similar
postoperative oncological outcome for patients with re-
sectable pancreatic ductal adenocarcinoma located in
the body/tail or head of the pancreas. Therefore, the
overall poorer survival in patients with tumors located
in the pancreatic body or tail appears to be solely due to
delayed diagnosis of disease with advanced stage and
limited therapeutic options.
Conclusion
Patients with resectable pancreatic ductal adenocarcin-
oma located in the body and tail of the pancreas display
a similar postoperative oncological outcome despite lar-
ger tumors when compared to patients with resectable
tumors located in the pancreatic head.
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